Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (ARCH)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03848832 |
|
Recruitment Status :
Recruiting
First Posted : February 21, 2019
Last Update Posted : August 20, 2019
|
Sponsor:
GW Research Ltd
Information provided by (Responsible Party):
GW Research Ltd
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in patients with Rett syndrome.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Rett Syndrome RTT | Drug: GWP42003-P Drug: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 252 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome |
| Actual Study Start Date : | July 29, 2019 |
| Estimated Primary Completion Date : | August 2021 |
| Estimated Study Completion Date : | September 2021 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Rett syndrome
MedlinePlus related topics:
Rett Syndrome
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 5 mg/kg/day GWP42003-P
100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
|
Drug: GWP42003-P
GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Other Names:
|
|
Experimental: 15 mg/kg/day GWP42003-P
100 mg/mL GWP42003-P oral solution. Taken twice daily (morning and evening).
|
Drug: GWP42003-P
GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Other Names:
|
|
Placebo Comparator: Placebo
Placebo oral solution (0 mg/mL GWP42003-P) volume matched to 5 mg/kg/day or 15 mg/kg/day GWP42003-P. Taken twice daily (morning and evening).
|
Drug: Placebo
Placebo oral solution containing the excipients sesame oil and anhydrous ethanol with added beta-carotene, sweetener (sucralose) and strawberry flavoring. |
Primary Outcome Measures :
- Rett Syndrome Behaviour Questionnaire (RSBQ) [ Time Frame: 24 weeks ]RSBQ is a caregiver-completed questionnaire that measures the frequency of current disease characteristics (45 items); each item rated on a 3-point scale (0-2). Higher scores represent greater severity.
- Clinical Global Impressions - Improvement (CGI-I) [ Time Frame: 24 weeks ]CGI-I is a 7-point scale that requires the clinician to assess how much a patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. (1 = very much improved, to 7 = very much worse.)
Secondary Outcome Measures :
- Rett Syndrome Behavior Questionnaire subscales [ Time Frame: 24 weeks ]
The 45 items in the caregiver-completed Rett Syndrome Behavior Questionnaire encompass 8 subscales:
1) general mood, 2) breathing problems, 3) hand behaviors, 4) face movements, 5) body rocking/expressionless face, 6) night-time behaviors, 7) anxiety/fear, 8) walking/standing. Higher scores represent greater severity.
- Clinician Global Impressions - Severity Scale (CGI-S) [ Time Frame: 24 weeks ]CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment relative to the clinician's experience with patients who have the same diagnosis, rating from 1 = normal, not at all ill, to 7 = extremely ill.
- 9-items Motor Behavioral Assessment (MBA-9) [ Time Frame: 24 weeks ]MBA-9 was derived from the full MBA scale (37 Rett syndrome symptoms) by selecting the items deemed amenable to change and which reflect areas of meaningful clinical change. The severity of current symptoms are rated by the investigator on a 5-point numerical scale, from 0 = normal or never, to 4 = very severe or constant. Higher total scores represent greater severity.
- Children's Sleep Habits Questionnaire (CSHQ) [ Time Frame: 24 weeks ]CSHQ is a caregiver-completed sleep screening instrument designed for school-aged children, including 33 items within 8 subscales reflecting the following sleep domains:1) bedtime resistance, 2) sleep onset delay, 3) sleep duration, 4) sleep anxiety, 5) night wakings, 6) parasomnias, 7) sleep-disordered breathing, 8) daytime sleepiness. Each item is answered with 1 of 3 markers: "usually" for 5 or more times a week, "sometimes" for 2-4 times a week, and "rarely" for never or 1 time a week. Higher scores reflect more disturbed sleep behaviour.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Patient (if possessing adequate understanding, in the investigator's opinion) and/or her parent(s)/legal representative is willing and able to give informed consent/assent for participation in the trial.
- Patient and her caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements (including the completion of all caregiver assessments by the same caregiver throughout the trial).
- Patient must weigh at least 9 kg.
- Clinical diagnosis of Rett syndrome (typical or atypical), defined according to RettSearch Consortium criteria.
- Confirmed genetic mutation of the MECP2 gene.
- Patient must be post-regression (≥ 6 months since last loss of hand use or verbal language or gross motor regression).
- All medications or interventions (including antiepileptic drugs [AEDs] and non-pharmacological interventions - dietary supplements, probiotics, physical therapy, speech therapy, etc.) for Rett syndrome-related symptoms must have been stable for 4 weeks prior to screening and the patient/caregiver must be willing to maintain a stable regimen throughout the trial.
- Ability to swallow the investigational medicinal product (IMP) provided as a liquid solution, or the ability for IMP to be delivered via gastrostomy (G) or nasogastric (NG) feeding tube (only G-or NG-tubes made from polyurethane or silicon are allowed).
- Patient and/or parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
- Patient and/or parent(s)/legal representative is willing to allow the patient's primary care practitioner (if she has one) and consultant (if she has one) to be notified of participation in the trial, if the primary care practitioner/consultant is different to the investigator.
Key Exclusion Criteria:
- Patient meets exclusion criteria for Rett syndrome diagnosis (traumatic brain injury, neurometabolic disease, or severe infection that causes neurological problems; grossly abnormal psychomotor development in the first 6 months of life).
- Patient has clinically significant abnormal laboratory values, in the investigator's opinion.
- Patient is taking more than 2 concurrent AEDs.
- Any history of suicidal behavior or any suicidal ideation in the last month or at screening.
- Clinically relevant abnormalities in the ECG measured at screening or randomization.
- Concurrent cardiovascular conditions which will, in the investigator's opinion, interfere with the ability to assess her ECGs or put the patient at risk because of participation in the trial.
- First or second degree relative with a history of significant ECG abnormalities, in the opinion of the investigator (e.g. cardiac arrest, sudden death).
- Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP (active or placebo), such as sesame oil.
- Patient has significantly impaired hepatic function at screening, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN) or total bilirubin > 2 × ULN.
- Pregnant (positive pregnancy test) or lactating.
- Received an IMP within the 3 months prior to screening.
- Patient has been taking felbamate for less than 1 year prior to screening.
- Currently using or has used recreational or medicinal cannabis, cannabinoid-based medications (including Sativex®), or cannabidiol oral solutions (including CBD-OS [GWP42003-P]) within the 3 months prior to screening and is unwilling to abstain for the duration of the trial.
- Patient has a positive delta-9-tetrahydrocannabinol (THC) test at screening.
- Any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory) or significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, may influence the result of the trial, or the patient's ability to participate in the trial.
- Any abnormalities identified following a physical examination of the patient that, in the opinion of the investigator, would jeopardize the safety of the patient if she took part in the trial.
- Patient has been previously randomized into this trial.
- Patient has travel outside the country of residence planned during the trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03848832
Contacts
| Contact: Medical Information | +44 (0) 1223 266 800 | medinfo@gwpharm.com, medinfo@greenwichbiosciences.com |
Locations
Show 17 study locations
Sponsors and Collaborators
GW Research Ltd
| Responsible Party: | GW Research Ltd |
| ClinicalTrials.gov Identifier: | NCT03848832 |
| Other Study ID Numbers: |
GWND18064 2018-003370-27 ( EudraCT Number ) |
| First Posted: | February 21, 2019 Key Record Dates |
| Last Update Posted: | August 20, 2019 |
| Last Verified: | August 2019 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by GW Research Ltd:
|
Cannabidiol CBD Epidiolex GWP42003-P |
Additional relevant MeSH terms:
|
Rett Syndrome Syndrome Disease Pathologic Processes Mental Retardation, X-Linked Intellectual Disability Neurobehavioral Manifestations |
Neurologic Manifestations Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Epidiolex Anticonvulsants |